Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”
S. Hashimoto (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), K. Eger (Amsterdam, Netherlands), P. Mau-Asam (Amsterdam, Netherlands), H. Hofstee (Leiden, Netherlands), S. Bendien (The Hague, Netherlands), G. Braunstahl (Rotterdam, Netherlands), M. Broeders (’s-Hertogenbosch, Netherlands), L. Imming (Enschede, Netherlands), B. Langeveld (Deventer , Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), K. Oud (Ede, Netherlands), K. Patberg (Zwolle, Netherlands), F. Smeenk (Eindhoven, Netherlands), E. Romme (Arnhem, Netherlands), M. Van Bezouw (Amsterdam, Netherlands), M. Van De Ven (Arnhem, Netherlands), A. Van Veen (Nijmegen, Netherlands), E. Van Velzen (Amersfoort, Netherlands), I. Van Veen (Enschede, Netherlands), E. Weersink (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Leiden, Netherlands), E. Bel (Amsterdam, Netherlands), R. Team (Amsterdam, Netherlands)
Source: International Congress 2022 – Asthma biologics in real life studies
Session: Asthma biologics in real life studies
Session type: Thematic Poster
Number: 2402
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hashimoto (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), K. Eger (Amsterdam, Netherlands), P. Mau-Asam (Amsterdam, Netherlands), H. Hofstee (Leiden, Netherlands), S. Bendien (The Hague, Netherlands), G. Braunstahl (Rotterdam, Netherlands), M. Broeders (’s-Hertogenbosch, Netherlands), L. Imming (Enschede, Netherlands), B. Langeveld (Deventer , Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), K. Oud (Ede, Netherlands), K. Patberg (Zwolle, Netherlands), F. Smeenk (Eindhoven, Netherlands), E. Romme (Arnhem, Netherlands), M. Van Bezouw (Amsterdam, Netherlands), M. Van De Ven (Arnhem, Netherlands), A. Van Veen (Nijmegen, Netherlands), E. Van Velzen (Amersfoort, Netherlands), I. Van Veen (Enschede, Netherlands), E. Weersink (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Leiden, Netherlands), E. Bel (Amsterdam, Netherlands), R. Team (Amsterdam, Netherlands). Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”. 2402
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|